Drug intelligence / Profile preview

tiotropium-Kindeva Drug Delivery

Development stage
Unknown
Lead developer
Kindeva Drug Delivery
Modality
Small Molecules
Administration
Inhalation
01

Overview

Tiotropium-Kindeva Drug Delivery is a pressurized metered-dose inhaler (pMDI) formulation of tiotropium, a long-acting muscarinic antagonist (LAMA). Developed by **Kindeva Drug Delivery** (a company formed from the acquisition of 3M's Drug Delivery Systems business), this product is formulated as a solution-based aerosol, which offers pharmaceutical advantages over traditional suspension formulations in terms of delivery consistency. The device delivers a dose of 5 mcg per actuation. It is designed for the maintenance treatment of **chronic obstructive pulmonary disease (COPD)** and **asthma**, functioning by inhibiting M3 receptors in the airway smooth muscle to induce bronchodilation. Clinical development has included Phase I pharmacokinetic crossover studies comparing the product's steady-state absorption to the reference branded product, Spiriva Respimat.

Brand names
Tiotropium Easyhaler
Other names
tiotropium pMDI (Kindeva Drug Delivery)tiotropium pressurized metered-dose inhalertiotropium inhalation aerosol
02

Targets

M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)

Beyond the preview

Go deeper on tiotropium-Kindeva Drug Delivery.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tiotropium-Kindeva Drug Delivery.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call